Clinical Trials Logo

Prodromal Schizophrenia clinical trials

View clinical trials related to Prodromal Schizophrenia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03149107 Terminated - Clinical trials for Prodromal Schizophrenia

"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"

ESPRIT-B1
Start date: September 1, 2016
Phase: Phase 3
Study type: Interventional

Schizophrenia is a severe mental disorder associated with significant impairments in affective, cognitive and social functioning. Consequently, a special interest in the prevention of schizophrenia and psychotic disorders has emerged. Pharmacological as well as psychological interventions show promising preventive effects. The purpose of this multicentric study is the investigation of possible preventive effects of a treatment combination containing a psychotherapy form and medication (N-Acetylcytein - NAC) in individuals with an enhanced risk for developing schizophrenia. Both treatment forms may reduce the risk in this population due to their specific properties: The psychotherapy can improve social skills, whereas NAC is supposed to develop its protective effects on neuronal level due to its antiinflammatory properties. The investigators will examine the preventive effects by measuring transition rates to psychosis after treatment as well as improvements in social, affective and cognitive functioning.

NCT ID: NCT00169949 Terminated - Clinical trials for Prodromal Schizophrenia

Aripiprazole Treatment of the Prodrome

Start date: January 2004
Phase: N/A
Study type: Interventional

The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden changes in functioning.